

Synthesis and biological evaluation against Leishmania donovani of novel hybrid molecules containing indazole-based 2-pyrone scaffolds

M. El Ghozlani, L. Bouissane, M. Berkani, S. Mojahidi, A. Allam, Christophe Menendez, S. Cojean, M. Loiseau, Michel Baltas, M. Rakib

▶ To cite this version:

M. El Ghozlani, L. Bouissane, M. Berkani, S. Mojahidi, A. Allam, et al.. Synthesis and biological evaluation against Leishmania donovani of novel hybrid molecules containing indazole-based 2-pyrone scaffolds. MedChemComm, 2019, 10 (1), pp.120-127. 10.1039/c8md00475g. hal-02059320

HAL Id: hal-02059320 https://hal.science/hal-02059320v1

Submitted on 16 Feb 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Synthesis and biological evaluation against Leishmania donovani of novel hybrid molecules containing indazole-based 2-pyrone scaffolds

M. El Ghozlani,^a L. Bouissane,^a M. Berkani,^a S. Mojahidi,^a A. Allam,^a C. Menendez,^b S. Cojean,^c P. M. Loiseau,^c M. Baltas,^b and E. M. Rakib^a*

^cChimiothérapie Antiparasitaire, UMR 8076 CNRS Faculté de Pharmacie, Université Paris-Saclay, Rue Jean-Baptiste Clément, F-92290 Chatenay-Malabry, France

E-mail: elmostapha1@ymail.com

Introduction

Hybridation of two different bioactive molecules with different mechanism of action is one of the methods that are being adopted to treat different diseases. From the last decades, the synthesis of hybrid molecules by the combination of different biologically relevant moieties has been under intense research along with their evaluation as pharmacological agents and potent drugs. A number of reports is focused on the biological potential of hybrid molecules with particular mention of those exhibiting anti-inflammatory, anti-cancer, anti-infectious like anti-fungal, anti-tuberculosis, anti-malarial, and antileishmanial activities.¹⁻⁵ For hybrid molecules containing indazole-based heterocycle scaffolds, only a few examples have been developed and reported in the literature as versatile chemotherapeutic agents and have found wide biological applications such as kinase inhibitors (pazopanib),⁶ antibacterial,⁷ receptor antagonist,⁸ and anticancer agents⁹. Three papers are reported on the antileishmanial activity of 5-nitroindazole derivatives.¹⁰⁻¹² Biological evaluation of the studied indazoles has shown that some compounds exhibit adequate *in vitro* leishmanicidal activity against different parasite strains.


2-Pyrone is an important class heterocyclic scaffold. Due to its pharmacophore properties, synthesis of hybrid derivatives bearing 2-pyrone moiety has attracted much attention; most of the compounds display strong biological activities such as cytotoxic, antibiotic and antifungal.¹³⁻¹⁶ It is also known that some pyrones exhibit antileishmanial activity.^{17,18} In that context, we planned to explore the possibility of introducing a 2-pyrone into indazole ring. We wish to report here the reductive coupling of *N*-alkyl-6(5)-nitroindazoles and 4-hydroxy-6-methyl-2-pyrone in order to obtain indazole/pyrone hybrid compounds and their inhibition activity against the axenic and intramacrophage amastigotes of *Leishmania donovani*.

Results and discussion

Chemistry

Synthesis of compounds 2a-d and 3a-d

Preparation of the starting materials, *N*-alkyl-6-nitroindazoles **2a-d** and **3a-d** and *N*-alkyl-3-chloro-6-nitroindazoles **2e-g** and **3e-g** were accomplished by simple alkylation of 6-nitroindazoles **1a,b** using experimental conditions recently developed by our group¹⁹ (Scheme 1).




Scheme 1.Synthesis of N-alkyl-6-nitroindazoles

After chromatographic separation and isolation of each *N*-alkyl-6-nitroindazole isomer, we examined their reactivity and that of their chlorinated derivatives 2a-h and 3a-h with 4-hydroxy-6-methyl-2-pyrone 4 in the presence of different reducing agents (SnCl₂/AcOH and In/AcOH in THF). By using an excess of anhydrous Indium and acetic acid respectively in comparison to reagents 2/3 and 4, we obtained after reflux in THF the

^aLaboratoire de Chimie Organique et Analytiques, Faculté des Sciences et Techniques, Université Sultan Moulay Slimane, B.P. 523, Béni-Mellal, Morocco. ^bUniversité Paul Sabatier, Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique, UMR-CNRS 5068, 118 route de Narbonne, 31062 Toulouse cedex 9, France

corresponding (3*E*)-3-(1-(*N*-alkyl-1*H*-indazol-6yl)amino)ethylidene)-6-methyl-3*H*-pyran-2,4-diones **5a–h** and **6a–h** in good yields 68–85% (Scheme 2). When we used $SnCl_2$ as the reductive system of nitroindazole derivatives, the yields of compounds **5a–h** and **6a–h** were slightly improved (72-91%).





All the structures of the obtained products **5a–h** and **6a–h** were determined by a detailed examination of their NMR data. Furthermore, the structure of product **5c** was unambiguously confirmed through X-ray crystallographic analysis (Figure 1).²⁰





Figure 1: X-ray crystal structure of 5c


Looking at the influence of the structure of the starting 6-nitro-*N*-alkyl-indazoles on the reduction/coupling yields in the presence of stannous chloride, we observed in all cases, that the alkylated indazoles in the *N*-1 position **5a-h** show better yields (78-91%) than the alkylated indazoles in the *N*-2 position **6a-h** (72-82%). Compounds **2c** and **2d** (substituted at N-1 with an allyl or a benzyl group) gave the hybrid molecules **5c,d** with excellent yields (91% and 88%, respectively).

A plausible mechanism was proposed to explain the formation of (3E)-3-(1-(*N*-alkyl-1*H*-indazol-6yl)amino)ethylidene)-6-methyl-3*H*-pyran-2,4-diones **5a–h**. First, the usual reduction of the nitro group generates the corresponding amine. Thereafter the attack of the amine on the carbonyl group of the dehydroacetic acid formed by acylation of the 4-hydroxy-6-methyl-2-pyrone with the acetic acid gave intermediate [**A**]. Dehydration of H₂O from [**A**], afforded the desired compounds **5a–h** (Scheme 3). It should be noted that, we performed reaction between 1-methyl-6-nitroindazole **2a** with dehydroacetic acid in the presence of SnCl₂ in THF with acetic acid; we isolated compound **5a** in good yield.




Scheme 3. Plausible mechanism of synthesis of 5a-h.

Encouraged by this result, we decided to enlarge the scope of this methodology to the synthesis of other hybrid molecules containing indazole and 2-pyrone moieties. Reaction of *N*-alkyl-5-nitroindazoles **7a–c** and **8a-c** with 4-hydroxy-6-methyl-2-pyrone **4** using the optimized reaction conditions (Scheme 4), afforded as expected compounds **9a–c** and **10a–c** with yields varying between 76%-92%. We obtained the (*3E*)-3-(1-((1-alkyl-indazol-5-yl)amino)ethylidene)-6-methyl-3*H*-pyran-2,4-diones **9a–c** in good yields (87-92%) while the *N*-2 alkylated indazoles **10a–c** were obtained in 76-84%. The highest yields were obtained by the reduction of nitroindazole derivatives with stannous chloride.




Scheme 4. Synthesis of compounds 9a–c and 10a–c.

Yields of compounds 5a-h and 6a-h in the presence of In or SnCl₂ as reductive system of N-alkyl-6-nitroindazole derivatives



*Isolated yield after column chromatography



Yields of compounds 9a-c and 10a-c in the presence of In or SnCl₂ as reductive system of N-alkyl-5-nitroindazole derivatives

Biological evaluation against L. donovani

The synthesized compounds were tested first for their cytotoxicity. Among 19 compounds, only three of them exhibited cytotoxicity with CC_{50} values around 6.25 μ M and all the other were not cytotoxic at all at 100 μ M. The compounds were then evaluated *in vitro* for antileishmanial activity against axenic and intramacrophage amastigotes of *L. donovani*. In this evaluation, the activity was expressed in IC₅₀ (concentration inhibiting the parasite growth by 50%).

Table 1. Antileishmanial activities of the synthesized compounds: Results are expressed as the concentration inhibiting parasite growth by 50% (IC_{50}).

	$IC_{50} \pm SD \ \mu M$		CC ₅₀ ± SD (μM)
Compounds	L. d. LV9 axenic	L. d. LV9 intramacrophage	Cytotoxicity on
-	amastigotes	amastigotes	macrophages
5a	>100	>100	>100
5b	>100	>100	>100
5c	>100	>100	>100
5d	>100	>100	>100
5e	>100	>100	>100
5f	10.99 ± 1.79	6.50 ± 1.25	6.23±0.74
5g	>100	>100	>100
5h	62.56 ± 1.25	49.89 ± 4.69	>100
6b	>100	>100	>100
6c	>100	>100	>100
6d	49.64 ± 3.19	57.38 ± 6.75	>100
6e	11.89 ± 1.28	3.25 ± 1.99	6.26±0.39
6f	2.48 ± 1.02	2.25 ± 1.89	6.25±0.47
6h	>100	>100	>100
9a	>100	>100	>100
9b	>100	>100	>100
9c	>100	>100	>100
10a	>100	>100	>100
10b	>100	>100	>100
AmB	0.201±0.080	0.115±0,090	4.23±0.32

Amphotericin B (AmB) was used as the reference drug

Among the compounds **5a-h** possessing various substituents at the N-1 position and a hydrogen or chlorine atom at the C-3 position of the indazole ring, only **5f** and to a lesser extent **5h** presented interesting activities. As shown in table 1, **5h** showed moderate antileishmanial activity against both axenic and intramacrophage amastigotes (IC_{50} of 62.56 ± 1.25 and

49.89 ± 4.69 μ M) whereas derivative **5f** (substituted at C-3 with a chlorine atom and at *N*-1 with an ethyl group) showed the greatest activity (IC₅₀ of 10.99 ± 1.79 and 6.50 ± 1.25 μ M).

Regarding the series of compounds **6b-h** (*N*-2 alkylated), we observed that three compounds **6d-f** displayed fair to very good activities on both intramacrophage and axenic amastigotes with IC_{50} values about ten times higher than those of amphotericin B, the reference compound. The most active compound **6f** (substituted at C-3 with a chlorine atom and at *N*-2 with an ethyl group) displayed IC_{50} of 2.48 ± 1.02 µM against *L. donovani* axenic amastigotes and, interestingly, an IC_{50} of 2.25 ± 1.89 µM against the intramacrophage ones. Compound **6e** which is alkylated at *N*-2 with methyl group, presented an almost four times better activity against intramacrophage amastigote than axenic ones (IC_{50} of 3.25 ± 1.99 *vs* 11.89 ± 1.28µM).

In comparison between the two series **5a-h/6b-h** we can observe that *N*-2 alkylated derivatives are the most active and among them those bearing a chlorine atom at the C-carbon atom of the indazole ring. Nevertheless, cytotoxicity on macrophage of active compounds tested remains quite strong and in a log range of their antileishmanial activities ($CC_{50} = 6.25 \mu M$).

Finally, looking at the influence of the position of pyrone attached to indazole on the structure activity relationship, we observed that compounds **9a-c** and **10a-c** (*N*-alkylated and indazole substituted at position 5 with pyrone) did not exhibit any antileishmanial activity ($IC_{50} > 100 \mu$ M). When looking at the Selectivity Index (SI) values, defined as the ratio between CC_{50}/IC_{50} in intracellular amastigotes, the most promising compound is compound **6f** (SI=2.77), followed by compound **6e** (SI=1,92), then **5f** (SI=0.96), this last compound exhibiting no margin between activity and cytotoxicity.

Conclusions

We have developed a simple and efficient synthesis of (3E)-3-(1-((*N*-alkyl-indazol-6-yl)amino)ethylidene)-6-methyl-3*H*-pyran-2,4-diones and (3E)-3-(1-((*N*-alkyl-indazol-5-yl)amino)ethylidene)-6-methyl-3*H*-pyran-2,4-diones by reductive coupling of *N*-alkyl-6(5)-nitroindazoles with 2-pyrone using indium or stannous chloride in THF in the presence of acetic acid. By using SnCl₂/AcOH in THF at 80°C with cheaper cost, we realized a methodology which provided high yields, short reaction time, easy work-up, purification of products by chromatographic method and clean reaction. Antileishmanial activity of 19 indazole-pyrone hybrid derivatives was studied, with compounds efficient against the intramacrophage and axenic form of the parasite. The remarkable antileishmanial activity obtained for **6f** (IC₅₀ values of 2.48 ± 1.02 µM and 2.25 ± 1.89 µM respectively on axenic and intramacrophage amastigotes) is moderated by its cytotoxicity. Considering the mechanism of action of both the series, the results obtained in this paper prompt us to develop further pharmacomodulations in order to diminish the cytotoxicity and enhance the antileishmanial activity. Therefore, compound **6f**, the most promising compound from this series, will be the basis for further pharmacomodulations.

Experimental

Chemistry

Melting points were determined using a Büchi-Tottoli apparatus. ¹H and ¹³C NMR spectra were recorded in CDCl₃, DMSO-d₆ and solution (unless otherwise specified) with TMS as an internal reference using a Bruker AC 300 (¹H) or 75MHz (¹³C) instruments. Chemical shifts are given in δ parts per million (ppm) downfield from TMS. Multiplicities of ¹³C NMR resources were assigned by distortionless enhancement by polarization transfer (DEPT) experiments. Low-resolution mass spectra (MS) were recorded on a Perkin-Elmer Sciex API 3000 spectrometer. Column chromatography was carried out on SiO₂ (silica gel 60 Merck 0.063–0.200 mm). Thin-layer chromatography (TLC) was carried out on SiO₂ (silica gel 60, F 254 Merck 0.063–0.200 mm), and the spots were located with UV light. Commercial reagents were used without further purification unless stated.

General procedure for the synthesis of compounds 5a-h, 6a-h, 9a-c and 10a-c.

N-alkyl-6(5)-nitroindazoles (1.0 mmol) were added to a mixture of anhydrous $SnCl_2$ powder (460 mg, 4.0 mmol), and acetic acid (0.572 mL, 10 mmol) in tetrahydrofuran (10 mL), followed by the addition of 2-pyrone (1.0 mmol) in THF (15 mL). The reaction mixture was stirred at 80 °C for 4 to 6 h. After the reaction was completed, the mixture was diluted with ethyl acetate (30 mL), poured into 10% NaHCO₃ (30 mL), and then extracted with ethyl acetate (50 mL x 3). The combined organic extracts were dried over MgSO₄, filtered, and concentrated. The residue was purified by column chromatography on silica gel using ethyl acetate/hexane (3:7) to afford the desired products in good yields. ¹H NMR, ¹³CNMR and DEPT copies of selected compounds are given in the supporting information.

(3E)-3-(1-(1-Methyl-1*H*-indazol-6-ylamino)ethylidene)-6-methyl-3*H*-pyran-2,4-dione (5a): Yield: 81%; mp 164-168 °C; ¹H NMR (DMSO-d₆): δ 2.12 (s, 3H, CH₃), 2.55 (s, 3H, CH₃), 4.03 (s, 3H, NCH₃), 5.85 (s, 1H, =CH), 7.08 (dd, 1H, J = 8.4 Hz, J = 1.5 Hz), 7.73 (d, 1H, J = 1.2 Hz), 7.84 (d, 1H, J = 8.4 Hz), 8.10 (s, 1H, H-3), 15.83 (s, 1H, NH); ¹³C NMR (DMSO-d₆): δ 19.8 (CH₃), 20.6 (CH₃), 36.0 (NCH₃), 97.1 (C), 107.2 (CH), 118.9 (CH), 122.4 (CH), 123.0 (C), 133.2 (CH-3), 134.4 (C), 139.9 (C), 162.8 (C),

163.9 (C), 175.7 (CO), 184.4 (CO); EI-MS (m/z) = 298 $[M+1]^+$, Anal. Calcd for $C_{16}H_{15}N_3O_3$; C, 64.64; H, 5.09; N, 14.13. Found: C, 64.71; H, 5.02; N, 14.24.

(3*E***)-3-(1-(2-Methyl-2***H***-indazol-6-ylamino)ethylidene)-6-methyl-3***H***-pyran-2,4-dione (6a): Yield: 75%; 192-194 °C; ¹H NMR (CDCl₃): δ 2.21 (s, 3H, CH₃), 2.66 (s, 3H, CH₃), 4.43 (s, 3H, NCH₃), 5.88 (s, 1H, =CH), 7.08 (dd, 1H, J = 8.4 Hz, J = 1.5 Hz), 7.71 (d, 1H, J = 1.2 Hz), 7.80 (d, 1H, J = 8.4 Hz), 8.21 (s, 1H, H-3), 15.81 (s, 1H, NH); ¹³C NMR (CDCl₃): δ 20.1 (CH₃), 20.7 (CH₃), 46.7 (NCH₃), 97.9 (C), 107.0 (CH), 112.0 (CH), 120.4 (C), 121.8 (CH), 122.8 (CH), 123.7 (C), 125.2 (CH-3), 139.0 (C), 164.0 (C), 175.1 (CO), 184.9 (CO); EI-MS (m/z) = 298 [M+1]⁺, Anal. Calcd for C₁₆H₁₅N₃O₃; C, 64.64; H, 5.09; N, 14.13. Found: C, 64.75; H, 5.05; N, 14.18.**

(3*E***)-3-(1-(1-Ethyl-1***H***-indazol-6-ylamino)ethylidene)-6-methyl-3***H***-pyran-2,4-dione (5***b***): Yield: 86%; mp 177-179 °C; ¹H NMR (CDCl₃): δ 1.54 (t, 3H, CH₃, J= 7.2 Hz), 2.21 (s, 3H, CH₃), 2.68 (s, 3H, CH₃), 4.46 (q, 2H, NCH₂, J= 7.2 Hz), 6.07 (s, 1H, =CH), 6.96 (dd, 1H, J = 8.4 Hz, J = 1.8 Hz), 7.27 (d, 1H, J = 1.2 Hz), 7.81 (d, 1H, J = 8.4 Hz), 8.07 (s, 1H, H-3), 15.57 (s, 1H, NH); ¹³C NMR (CDCl₃): δ 14.9 (CH₃), 20.1 (CH₃), 21.0 (CH₃), 44.1 (NCH₂), 98.2 (C), 106.1 (CH), 106.5 (CH), 118.7 (CH), 122.9 (CH), 123.4 (C), 132.7 (CH-3), 134.4 (C), 138.7 (C), 160.1 (C), 164.0 (C), 175.8 (CO), 184.0 (CO); EI-MS (m/z) = 312 [M+1]⁺, Anal. Calcd for C₁₇H₁₇N₃O₃; C, 65.58; H, 5.50; N, 13.50. Found: C, 65.67; H, 5.42; N, 13.64.**

(*3E*)-3-(1-(2-Ethyl-2*H*-indazol-6-ylamino)ethylidene)-6-methyl-3*H*-pyran-2,4-dione (6b): Yield: 72%; mp 159-161 °C; ¹H NMR (CDCl₃): δ 1.75 (t, 3H, CH₃, J = 7.2 Hz), 2.19 (s, 3H, CH₃), 2.66 (s, 3H, CH₃), 4.72 (q, 2H, NCH₂, J= 7.2 Hz), 5.91 (s, 1H, =CH), 7.03 (dd, 1H, J = 9.0 Hz, J = 1.2 Hz), 7.65 (d, 1H, J = 1.2 Hz), 7.83 (d, 1H, J = 9.0 Hz), 8.23 (s, 1H, H-3), 15.88 (s, 1H, NH); ¹³C NMR (CDCl₃): δ 15.6 (CH₃), 20.0 (CH₃), 20.7 (CH₃), 49.0 (NCH₂), 98.2 (C), 106.8 (CH), 111.4 (CH), 120.2 (C), 121.8 (CH), 122.6 (CH), 123.4 (C), 125.6 (CH-3), 138.7 (C), 164.2 (C), 175.6 (CO), 184.5 (CO); EI-MS (m/z) = 312 [M+1]⁺, Anal. Calcd for $C_{17}H_{17}N_3O_3$; C, 65.58; H, 5.50; N, 13.50. Found: C, 65.71; H, 5.38; N, 13.58.

(3E)-3-(1-(1-Allyl-1*H***-indazol-6-ylamino)ethylidene)-6-methyl-3***H***-pyran-2,4-dione (5c)**: Yield: 91%; mp 118-120 °C; ¹H NMR (CDCl₃): δ 2.21 (s, 3H, CH₃), 2.68 (s, 3H, CH₃), 5.04–5.06 (m, 2H, NCH₂), 5.13–5.28 (m, 2H, =CH₂), 5.97–6.06 (m, 1H, =CH), 6.13 (s, 1H, =CH), 6.97 (dd, 1H, J = 8.4 Hz, J = 1.8 Hz), 7.27 (d, 1H, J = 1.2 Hz), 7.82 (d, 1H, J = 8.4 Hz), 8.07 (s, 1H, H-3), 15.48 (s, 1H, NH); ¹³C NMR (CDCl₃): δ 20.1 (CH₃), 21.0 (CH₃), 52.1 (NCH₂), 98.2 (C), 106.5 (CH), 110.5 (CH), 118.5 (=CH₂), 118.8 (CH), 122.7 (CH), 123.7 (C), 132.1 (CH), 133.3 (CH), 134.3 (C), 139.2 (C), 163.9 (C), 164.7 (C), 176.0 (CO), 184.0 (CO); EI-MS (m/z) = 324 [M+1]⁺, Anal. Calcd for C₁₈H₁₇N₃O₃; C, 66.86; H, 5.30; N, 13.00. Found: C, 66.74; H, 5.42; N, 13.08.

(3*E***)-3-(1-(2-Allyl-2***H***-indazol-6-ylamino)ethylidene)-6-methyl-3***H***-pyran-2,4-dione (6c): Yield: 82%; mp 96-98 °C; ¹H NMR (CDCl₃): \delta 2.16 (s, 3H, CH₃), 2.64 (s, 3H, CH₃), 5.10–5.13 (m, 2H, NCH₂), 5.35–5.42 (m, 2H, =CH₂), 5.83 (s, 1H, =CH), 6.09–6.18 (m, 1H, =CH), 6.90 (dd, 1H, J = 8.4 Hz, J = 1.5 Hz), 7.54 (d, 1H, J = 1.0 Hz), 7.74 (d, 1H, J = 8.4 Hz), 8.10 (s, 1H, H-3), 15.71 (s, 1H, NH); ¹³C NMR (CDCl₃): \delta 19.9 (CH₃), 20.6 (CH₃), 56.3 (NCH₂), 97.4 (C), 107.2 (CH), 113.5 (CH), 120.5 (CH), 120.7 (=CH₂), 122.1 (CH), 122.7 (C), 123.9 (CH), 131.3 (CH), 147.3 (C), 163.4 (C), 163.8 (C), 175.6 (CO), 184.6 (CO); EI-MS (m/z) = 324 [M+1]⁺, Anal. Calcd for C₁₈H₁₇N₃O₃; C, 66.86; H, 5.30; N, 13.00. Found: C, 66.72; H, 5.38; N, 13.15.**

(3*E*)-3-{1-[1-(4-Methyl-benzyl)-1*H*-indazol-6-ylamino]-ethylidene}-6-methyl-3*H*-pyran-2,4-dione (5d): Yield: 88%; mp 98–100 °C; ¹H NMR (CDCl₃): δ 2.23 (s, 3H, CH₃), 2.31 (s, 3H, CH₃), 2.59 (s, 3H, CH₃), 5.58 (s, 2H, NCH₂), 5.79 (s, 1H, =CH), 6.94 (dd, 1H, J = 8.4 Hz, J = 1.8 Hz), 7.11-7.15 (m, 5H), 7.82 (d, 1H, J = 8.4 Hz), 8.11 (s, 1H, H-3), 15.37 (s, 1H, NH); ¹³C NMR (CDCl₃): δ 20.1 (CH₃), 21.1 (2CH₃), 53.3(NCH₂), 98.2 (C), 106.0 (CH), 106.6 (CH), 118.7 (CH), 122.9 (CH), 123.8 (C), 127.3 (2CH), 129.5 (C), 129.7 (2CH), 132.7 (C), 133.2 (CH), 134.2 (C), 138.1 (C), 139.2 (C), 163.4 (C), 175.1 (CO), 184.1 (CO); EI-MS (m/z) = 388 [M+1]⁺, Anal. Calcd for C₂₃H₂₁N₃O₃; C, 71.30; H, 5.46; N, 10.85. Found: C, 71.18; H, 5.57; N, 10.74.

(3*E*)-3-{1-[2-(4-Methyl-benzyl)-2*H*-indazol-6-ylamino]-ethylidene}-6-methyl-3*H*-pyran-2,4-dione (6d): Yield: 78%; mp 154-156 °C; ¹H NMR (CDCl₃): δ 2.16 (s, 3H, CH₃), 2.34 (s, 3H, CH₃), 2.64 (s, 3H, CH₃), 5.59 (s, 2H, NCH₂), 5.79 (s, 1H, =CH), 6.85 (dd, 1H, J = 8.4 Hz, J = 1.0 Hz), 7.17 (d, 1H, J = 7.8 Hz), 7.23 (d, 1H, J = 7.8 Hz), 7.52 (d, 1H, J = 1.0 Hz), 7.68 (d, 1H, J = 8.4 Hz), 7.95 (s, 1H, H-3), 15.72 (s, 1H, NH); ¹³C NMR (CDCl₃): δ 19.9 (CH₃), 20.5 (CH₃), 21.2 (CH₃), 57.5 (NCH₂), 97.5 (C), 107.2 (CH), 113.2 (CH), 120.6 (C), 120.7 (CH), 122.2 (CH), 124.3 (CH), 128.5 (2CH), 129.8 (2CH), 131.4 (C), 135.1 (C), 138.9 (C), 163.5 (C), 163.7 (C), 175.5 (CO), 184.6 (CO); EI-MS (m/z) = 388 [M+1]⁺, Anal. Calcd for C₂₃H₂₁N₃O₃; C, 71.30; H, 5.46; N, 10.85. Found: C, 71.21; H, 5.61; N, 10.78.

(3*E***)-3-(1-(3-Chloro-1-methyl-1***H***-indazol-6-ylamino)ethylidene)-6-methyl-3***H***-pyran-2,4-dione (5e): Yield: 78%; mp 185-187 °C; ¹H NMR (CDCl₃): δ 2.15 (s, 3H, CH₃), 2.58 (s, 3H, CH₃), 4.08 (s, 3H, NCH₃), 5.91 (s, 1H, =CH), 7.05 (d, 1H, J = 8.4 Hz), 7.20 (d, 1H, J = 1.0 Hz), 7.81 (d, 1H, J = 8.4 Hz), 15.65 (s, 1H, NH); ¹³C NMR (CDCl₃): δ 20.0 (CH₃), 20.7 (CH₃), 47.6 (NCH₃), 97.8 (C), 106.8 (CH), 107.1 (CH), 119.0 (CH), 121.0 (C), 121.4 (CH), 134.1 (C), 136.0 (C), 140.8 (C), 163.7 (C), 164.9 (C), 175.8 (CO), 184.6 (CO); EI-MS (m/z) = 332 (³⁵Cl) [M+1]⁺, 334 (³⁷Cl) [M+3]⁺ Anal. Calcd for C₁₆H₁₄ClN₃O₃; C, 57.93; H, 4.25; N, 12.67. Found: C, 57.82; H, 4.36; N, 12.54.**

(3*E***)-3-(1-(3-Chloro-2-methyl-2***H***-indazol-6-ylamino)ethylidene)-6-methyl-3***H***-pyran-2,4-dione (6e): Yield: 76%; mp 107-109 °C; ¹H NMR (CDCl₃): δ 2.16 (s, 3H, CH₃), 2.63 (s, 3H, CH₃), 4.17 (s, 3H, NCH₃), 5.77 (s, 1H, =CH), 6.88 (dd, 1H, J = 8.7 Hz, J = 1.5 Hz), 7.42 (d, 1H, J = 1.5 Hz), 7.62 (d, 1H, J = 8.7 Hz), 15.88 (s, 1H, NH); ¹³C NMR (CDCl₃): δ 19.9 (CH₃), 20.5 (CH₃), 37.8 (NCH₃),**

Med. Chem. Commun., 2019, 10, 120-127

97.5 (C), 107.2 (C), 114.2 (CH), 111.8 (C), 118.1 (C), 120.1 (CH), 120.6 (CH), 135.0 (C), 147.1 (C), 163.4 (C), 175.5 (CO), 184.8 (CO); EI-MS (m/z) = 332 (35 CI) [M+1]⁺, 334 (37 CI) [M+3]⁺ Anal. Calcd for C₁₆H₁₄CIN₃O₃; C, 57.93; H, 4.25; N, 12.67. Found: C, 57.78; H, 4.34; N, 12.52.

(3*E***)-3-(1-(3-Chloro-1-ethyl-1***H***-indazol-6-ylamino)ethylidene)-6-methyl-3***H***-pyran-2,4-dione (5f) : Yield: 77%; mp 67-69 °C; ¹H NMR (CDCl₃): δ 1.51 (t, 3H, CH₃, J= 7.2 Hz), 2.26 (s, 3H, CH₃), 2.58 (s, 3H, CH₃), 4.40 (q, 2H, NCH₂, J= 7.2 Hz), 5.81 (s, 1H, =CH), 6.90 (dd, 1H, J = 8.7 Hz, J = 1.5 Hz), 7.45 (d, 1H, J = 1.5 Hz), 7.66 (d, 1H, J = 8.7 Hz), 15.82 (s, 1H, NH); ¹³C NMR (CDCl₃): δ 14.8 (CH₃), 20.2 (CH₃), 21.0 (CH₃), 44.5 (NCH₂), 97.8 (C), 107.4 (C), 114.1 (CH), 111.9 (C), 118.5 (C), 120.3 (CH), 120.8 (CH), 135.1 (C), 146.9 (C), 163.8 (C), 175.6 (CO), 184.2 (CO); EI-MS (m/z) = 346 (³⁵Cl) [M+1]⁺, 348 (³⁷Cl) [M+3]⁺ Anal. Calcd for C₁₆H₁₄ClN₃O₃; C, 59.05; H, 4.66; N, 12.15. Found: C, 59.18; H, 4.54; N, 12.22.**

(3*E*)-3-(1-(3-Chloro-2-ethyl-2*H*-indazol-6-ylamino)ethylidene)-6-methyl-3*H*-pyran-2,4-dione (6f) : Yield: 80%; mp 62-64 °C; ¹H NMR (CDCl₃): δ 1.45 (t, 3H, CH₃, J= 7.2 Hz), 2.20 (s, 3H, CH₃), 2.64 (s, 3H, CH₃), 4.72 (q, 2H, NCH₂, J= 7.2 Hz), 5.81 (s, 1H, =CH), 6.91 (dd, 1H, J = 8.4 Hz, J = 1.5 Hz), 7.45 (d, 1H, J = 1.5 Hz), 7.68 (d, 1H, J = 8.4 Hz), 15.78 (s, 1H, NH); ¹³C NMR (CDCl₃): δ 15.7 (CH₃), 20.0 (CH₃), 20.6 (CH₃), 48.8 (NCH₂), 97.8 (C), 107.1 (C), 113.9 (CH), 112.0 (C), 118.2 (C), 120.4 (CH), 120.8 (CH), 134.9 (C), 146.8 (C), 163.5 (C), 175.7 (CO), 184.5 (CO); EI-MS (m/z) = 346 (³⁵Cl) [M+1]⁺, 348 (³⁷Cl) [M+3]⁺ Anal. Calcd for C₁₆H₁₄ClN₃O₃; C, 59.05; H, 4.66; N, 12.15. Found: C, 59.24; H, 4.50; N, 12.28.

(3*E***)-3-(1-(1-Allyl-3-chloro-1***H***-indazol-6-ylamino)ethylidene)-6-methyl-3***H***-pyran-2,4-dione (5g):. Yield: 81%; mp 146-148 °C; ¹H NMR (CDCl₃): δ 2.23 (s, 3H, CH₃), 2.66 (s, 3H, CH₃), 4.95–4.98 (m, 2H, NCH₂), 5.18–5.30 (m, 2H, =CH₂), 5.82–6.02 (m, 1H, =CH), 6.14 (s, 1H, =CH), 7.02 (d, 1H, J = 8.4 Hz), 7.24 (d, 1H, J = 1.0 Hz), 7.77 (d, 1H, J = 8.4 Hz), 15.54 (s, 1H, NH); ¹³C NMR (CDCl₃): δ 20.1 (CH₃), 21.1 (CH₃), 52.5 (NCH₂), 97.1 (C), 106.3 (CH), 106.9 (CH), 118.9 (=CH₂), 119.3 (CH), 121.0 (C), 121.6 (CH), 131.7 (CH), 133.5 (C), 135.3 (C), 140.5 (C), 163.8 (C), 165.0 (C), 176.2 (CO), 184.0 (CO); EI-MS (m/z) = 358 (³⁵Cl) [M+1]⁺, 360 (³⁷Cl) [M+3]⁺ Anal. Calcd for C₁₈H₁₆ClN₃O₃; C, 60.43; H, 4.51; N, 11.74. Found: C, 60.32; H, 4.64; N, 11.63.**

(3E)-3-(1-(2-Allyl-3-chloro-2*H*-indazol-6-ylamino)ethylidene)-6-methyl-3*H*-pyran-2,4-dione (6g): Yield: 75%; mp 70-72 °C; ¹H NMR (CDCl₃): δ 2.18 (s, 3H, CH₃), 2.67 (s, 3H, CH₃), 5.08–5.12 (m, 2H, NCH₂), 5.32–5.40 (m, 2H, =CH₂), 5.86 (s, 1H, =CH), 6.10–6.17 (m, 1H, =CH), 6.92 (dd, 1H, J = 8.4 Hz, J = 1.5 Hz), 6.91 (dd, 1H, J = 8.4 Hz, J = 1.5 Hz), 7.45 (d, 1H, J = 1.5 Hz), 7.61 (d, 1H, J = 8.4 Hz), 15.77 (s, 1H, NH); ¹³C NMR (CDCl₃): δ 20.0 (CH₃), 20.6 (CH₃), 56.4 (NCH₂), 97.6 (C), 106.8 (C), 113.6 (CH), 112.0 (C), 118.2 (C), 120.4 (CH), 120.7 (=CH₂), 121.0 (CH), 131.5 (CH), 135.0 (C), 146.2 (C), 164.0 (C), 175.4 (CO), 184.8 (CO); EI-MS (m/z) = 358 (³⁵Cl) [M+1]⁺, 360 (³⁷Cl) [M+3]⁺ Anal. Calcd for C₁₈H₁₆ClN₃O₃; C, 60.43; H, 4.51; N, 11.74. Found: C, 60.28; H, 4.60; N, 11.61.

(3*E***)-3-(1-(1-Methyl-1***H***-indazol-5-ylamino)ethylidene)-6-methyl-3***H***-pyran-2,4-dione 9a: Yield: 92%; mp 173-175 °C; ¹H NMR (CDCl₃): \delta 2.23 (s, 3H, CH₃), 2.65 (s, 3H, CH₃), 4.13 (s, 3H, NCH₃), 6.24 (s, 1H, =CH), 7.20 (dd, 1H, J = 8.4 Hz, J = 1.8 Hz), 7.53 (d, 1H, J = 8.4 Hz), 7.57 (d, 1H, J = 1.2 Hz), 8.05 (s, 1H, H-3), 15.22 (s, 1H, NH); ¹³C NMR (CDCl₃): \delta 20.1 (CH₃), 21.0 (CH₃), 35.9 (NCH₃), 98.2 (C), 106.2 (CH), 110.5 (CH), 118.1 (CH), 123.8 (C), 124.1 (CH), 128.8 (C), 133.0 (CH-3), 138.9 (C), 164.1 (C), 164.9 (C), 176.3 (CO), 183.6 (CO); EI-MS (m/z) = 298 [M+1]⁺, Anal. Calcd for C₁₆H₁₅N₃O₃; C, 64.64; H, 5.09; N, 14.13. Found: C, 64.75; H, 5.18; N, 14.20.**

(3*E*)-3-(1-(2-Methyl-2*H*-indazol-5-ylamino)ethylidene)-6-methyl-3*H*-pyran-2,4-dione (10a): Yield: 84%; mp 142-144 °C; ¹H NMR (CDCl₃): δ 2.16 (s, 3H, CH₃), 2.61 (s, 3H, CH₃), 4.29 (s, 3H, NCH₃), 5.81 (s, 1H, =CH), 7.09 (dd, 1H, J = 8.4 Hz, J = 1.8 Hz), 7.48 (d, 1H, J = 1.8 Hz), 7.77 (d, 1H, J = 8.4 Hz), 8.02 (s, 1H, H-3), 15.59 (s, 1H, NH); ¹³C NMR (CDCl₃): δ 19.9 (CH₃), 20.5 (CH₃), 40.6 (NCH₃), 97.3 (C), 107.3 (CH), 116.8 (CH), 118.6 (CH), 121.4 (C), 124.9 (CH), 125.5 (CH-3), 130.5 (C), 146.8 (C), 163.4 (C), 163.8 (C), 175.7 (CO), 184.6 (CO); EI-MS (m/z) = 298 [M+1]⁺, Anal. Calcd for C₁₆H₁₅N₃O₃; C, 64.64; H, 5.09; N, 14.13. Found: C, 64.72; H, 5.21; N, 14.24.

(3*E*)-3-(1-(1-Ethyl-1*H*-indazol-5-ylamino)ethylidene)-6-methyl-3*H*-pyran-2,4-dione (9b): Yield: 87%; mp 156-158 °C; ¹H NMR (CDCl₃): δ 1.54 (t, 3H, CH₃, J= 7.2 Hz), 2.22 (s, 3H, CH₃), 2.65 (s, 3H, CH₃), 4.48 (q, 2H, NCH₂, J= 7.2 Hz), 6.21 (s, 1H, =CH), 7.19 (dd, 1H, J = 8.4 Hz, J = 1.8 Hz), 7.51 (d, 1H, J = 8.4 Hz), 7.58 (d, 1H, J = 1.5 Hz), 8.06 (s, 1H, H-3), 15.25 (s, 1H, NH); ¹³C NMR (CDCl₃): δ 14.9 (CH₃), 20.1 (CH₃), 20.9 (CH₃), 44.2 (NCH₂), 96.8 (C), 106.3 (CH), 110.4 (CH), 118.2 (CH), 123.9 (C), 124.1 (CH), 128.8 (C), 133.0 (CH-3), 138.0 (C), 164.1 (C), 164.8 (C), 176.2 (CO), 183.7 (CO); EI-MS (m/z) = 312 [M+1]⁺, Anal. Calcd for $C_{17}H_{17}N_3O_3$; C, 65.58; H, 5.50; N, 13.50. Found: C, 65.75; H, 5.41; N, 13.64.

(3*E***)-3-(1-(2-Ethyl-2***H***-indazol-5-ylamino)ethylidene)-6-methyl-3***H***-pyran-2,4-dione (10b): Yield: 76%; mp 113-115 °C; ¹H NMR (CDCl₃): δ 1.69 (t, 3H, CH₃, J = 7.2 Hz), 2.17 (s, 3H, CH₃), 2.62 (s, 3H, CH₃), 4.59 (q, 2H, NCH₂, J = 7.2 Hz), 5.83 (s, 1H, =CH), 7.13 (dd, 1H, J = 8.4 Hz, J = 1.8 Hz), 7.51 (d, 1H, J = 1.0 Hz), 7.82 (d, 1H, J = 8.4 Hz), 8.10 (s, 1H, H-3), 15.61 (s, 1H, NH); ¹³C NMR (CDCl₃): δ 15.7 (CH₃), 19.9 (CH₃), 20.5 (CH₃), 48.9 (NCH₂), 97.3 (C), 107.2 (CH), 117.0 (CH), 118.3 (CH), 121.0 (C), 124.0 (CH), 125.5 (CH-3), 130.7 (C), 145.7 (C), 163.5 (C), 163.8 (C), 175.7 (CO), 184.6 (CO); EI-MS (m/z) = 312 [M+1]⁺, Anal. Calcd for C₁₇H₁₇N₃O₃; C, 65.58; H, 5.50; N, 13.50. Found: C, 65.72; H, 5.38; N, 13.60.**

(3E)-3-(1-(1-Allyl-1*H***-indazol-5-ylamino)ethylidene)-6-methyl-3***H***-pyran-2,4-dione (9c): Yield: 90%; mp 90-92 °C; ¹H NMR (CDCl₃): δ 2.22 (s, 3H, CH₃), 2.65 (s, 3H, CH₃), 5.05–5.08 (m, 2H, NCH₂), 5.15–5.26 (m, 2H, =CH₂), 5.97–6.08 (m, 1H, =CH),**

6.19 (s, 1H, =CH), 7.17 (dd, 1H, J = 8.4 Hz, J = 1.8 Hz), 7.50 (d, 1H, J = 9.0 Hz), 7.58 (d, 1H, J = 1.8 Hz), 8.07 (s, 1H, H-3), 15.27 (s, 1H, NH); ¹³C NMR (CDCl₃): δ 20.1 (CH₃), 20.8 (CH₃), 52.1 (NCH₂), 96.9 (C), 106.5 (CH), 110.7 (CH), 118.1 (CH), 118.4 (=CH₂), 124.1 (CH), 124.3 (C), 128.9 (C), 132.2 (CH), 133.5 (CH), 138.5 (C), 164.1 (C), 164.7 (C), 176.2 (CO), 183.8 (CO); EI-MS (m/z) = 324 [M+1]⁺, Anal. Calcd for C₁₈H₁₇N₃O₃; C, 66.86; H, 5.30; N, 13.00. Found: C, 66.70; H, 5.37; N, 13.16.

(3*E*)-3-(1-(2-Allyl-2*H*-indazol-5-ylamino)ethylidene)-6-methyl-3*H*-pyran-2,4-dione (10c): Yield: 81%; mp 78-80 °C; ¹H NMR (CDCl₃): δ 2.18 (s, 3H, CH₃), 2.63 (s, 3H, CH₃), 5.16–5.19 (m, 2H, NCH₂), 5.40–5.46 (m, 2H, =CH₂), 5.92 (s, 1H, =CH), 6.05–6.20 (m, 1H, =CH), 7.15 (dd, 1H, J = 8.4 Hz, J = 1.5 Hz), 7.53 (d, 1H, J = 1.0 Hz), 7.68 (d, 1H, J = 8.4 Hz), 8.12 (s, 1H, H-3), 15.56 (s, 1H, NH); ¹³C NMR (CDCl₃): δ 19.9 (CH₃), 20.6 (CH₃), 56.2 (NCH₂), 97.6 (C), 106.9 (CH), 117.2 (CH), 118.3 (CH), 121.4 (=CH₂), 124.8 (CH), 121.7 (C), 128.8 (CH), 130.7 (CH), 132.4 (C), 163.8 (C), 163.9 (C), 175.8 (CO), 184.4 (CO); EI-MS (m/z) = 324 [M+1]⁺, Anal. Calcd for C₁₈H₁₇N₃O₃; C, 66.86; H, 5.30; N, 13.00. Found: C, 66.77; H, 5.43; N, 13.21.

Biology

Parasite and cell cultures. Promastigotes of the *Leishmania donovani* (MHOM/ET/67/HU3/LV9) were cultured in the dark at 26°C with 5% CO₂ in M199 complete medium containing M199 medium supplemented with 100 μ M adenosine, 0.5 mg/L hemin, 40 mM Hepes pH 7.4 and 10 % heat inactivated foetal bovine serum (HIFBS). Cultures of axenic amastigotes of *L. donovani* were obtained from late log promastigotes diluted at 1 x 10⁶/mL in M199 complete medium acidified at pH 5.5 and cultured at 37°C with 5% CO₂.

Macrophage. The macrophages RAW 264.7 were cultured at 37° C with 5% CO₂ in DMEM complete medium containing Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 100 U/mL penicillin-streptomycin, and 10% HIFBS.

Evaluation of compounds cytotoxicity. Cytotoxicity was evaluated on RAW 264.7 macrophages. Cells were plated in 96well microplates at a density of 2 x 10^4 cells per well. After an incubation of 24 h at 37°C with 5% CO₂, the medium was removed in each well, and 100 µL of DMEM complete medium containing two fold serial dilutions of the compounds was added to each well. After 48 h of incubation at 37°C with 5% CO₂, 10 µL of resazurin (450 µM) was added to each well, and further incubated in the dark for 4 h at 37°C with 5% CO₂. Cell viability was then monitored as described above. The cytotoxicity of the compounds was expressed as CC50 (Cytotoxic Concentration 50%: concentration inhibiting the macrophages growth by 50%).

In vitro **antileishmanial evaluation of compounds on axenic and intramacrophage amastigotes.** The evaluations of activity on axenic and intramacrophage amastigotes of *L. donovani* were adapted from the protocols previously described [19]. Briefly, for the evaluation on axenic amastigotes, two fold serial dilutions of the compounds were performed in 100 μ L of complete medium (see above) in 96-well microplates. Axenic amastigotes were then added to each well at a density of 10^6 /mL in a 200 μ L final volume. After 72 h of incubation at 37°C with 5 % CO₂, 20 μ L of resazurin (450 μ M) was added to each well and further incubated in the dark for 24 h at 37°C with 5% CO₂. In living cells, resazurin is reduced in resorufin and this conversion is monitored by measuring OD570nm (resorufin) and OD600nm (resazurin; Lab systems Multiskan MS). The activity of the compounds was expressed as IC₅₀ in μ M. Amphotericin B (AmB) was used as the reference drug.

Concerning the evaluation on intramacrophage amastigotes, RAW 264.7 macrophages were plated in 96-well microplates at a density of 2 x 104 cells per well and incubated for 24 h at 37°C with 5% CO2. Axenic amastigotes were differenciated as described above, centrifuged at 2,000 g for 10 min, resuspended in DMEM complete medium, and added to each well to reach a 16 :1 parasite to macrophage ratio. After 24 h of infection at 37°C with 5% CO₂, extracellular parasites were removed, and DMEM complete medium (100 μ L) containing two fold serial dilutions of the compounds from a maximal concentration of 100 μ M was added to each well. After 48 h of treatment, the medium was removed and replaced by Direct PCR Lysis Reagent (100 μ L; Euromedex) before 3 freeze-thaw cycles at room temperature, addition of 50 μ g/mL proteinase K, and a final incubation at 55°C overnight to allow cell lysis. 10 μ L of each cell extract was then added to 40 μ L of Direct PCR Lysis reagent containing Sybr Green I (0.05%; Invitrogen). DNA fluorescence was monitored using Mastercycler® realplex (Eppendorf). The activity of the compounds was expressed as IC₅₀ in μ M. Amphotericin B (AmB) was used as the reference drug.

Acknowledgements

We thank the University of Sultan Moulay Slimane, Beni-Mellal, for financial support and the National Centre for Scientific and Technical Research (CNRST), Rabat, for providing the NMR and X-ray crystallography of our compounds.

Conflict of Interest

The authors declare no competing interests

Notes and references

- 1 A. Shaveta, S. Mishra and P. Singh, Eur. J. Med. Chem. 2016, 124, 500–536.
- 2 A. Noor ul and A. Matloob, *Turk. J. Chem.* 2018, **42**, 1-20.
- 3 M. Matias, S. Silvestre, A. Falcao and G. Alves, Mini Rev. Med. Chem. 2017, 17, 486-517.
- 4 C-G. Wilson, F.Y. Andres and H-R. Angie, Curr. Med. Chem. 2018, 25, 3637-3679.
- 5 R.H. Dodd, C. Ouannès, M. Robert-Gèro and P. Potier, *J Med Chem.* 1989, **32**, 1272-1276.
- 6 P. A. Harris, A. Boloor, M. Cheung, R. Kumar, R.M. Crosby, R. G. Davis-Ward, A.H. Epperly, K.W. Hinkle, R.N. Hunter, J.H. Johnson, V.B. Knick, C.P. Laudeman, D.K. Luttrell, R.A. Mook, R.T. Nolte, S.K. Rudolph, J.R. Szewczyk, A.T. Truesdale, J.M. Veal and L. Wang, *J. Med. Chem.*, 2008, **51**, 4632–4640.
- 7 J. Zhang, Q. Yang, J.A.C. Romero, J. Cross, B. Wang, K.M. Poutsiaka, F. Epie, D. Bevan, Y. Wu, T. Moy, A. Daniel, B. Chamberlain, N. Carter, J. Shotwell, A. Arya, V. Kumar, J. Silverman, K. Nguyen, C. A. Metcalf, D. Ryan, B. Lippa and R.E Dolle, ACS Med. Chem. Lett. 2015, 6, 1080–1085.
- 8 K. G. Liu, A. J. Robichaud, R. C. Bernotas, Y. Yan, J.R. Lo, M-Y. Zhang, Z.A. Hughe, C. Huselton, G. M. Zhang, J. Y. Zhang, D. M. Kowal, D. L. Smith, L. E. Schechter and T. A. Comery, *J. Med. Chem.*, 2010, **53**, 7639–7646.
- 9 (a) A. Takeuchi, M. Hori, S. Sato, H. S. Ban, T. Kuchimaru, S. Kizaka-Kondoh, T. Yamori, H. Nakamura, *Med. Chem. Commun.*, 2012, **3**, 1455-1461; (b) N. Abbassi, H. Chicha, E. M. Rakib, A. Hannioui, M. Alaoui, A. Hajjaji, D. Geffken, C. Aiello, R. Gangemi, C. Rosano and M. Viale, *Eur. J. Med. Chem.* 2012, **57**, 240–249.
- 10 C. Fonseca-Berzal, A. Ibáñez-Escribano, N. Vela, J. Cumella, J.J. Nogal-Ruiz, J.A. Escario, P.B. da Silva, M.M. Batista, M.N.C. Soeiro, S. Sifontes-Rodríguez, A. Meneses-Marcel, A. Gómez-Barrio and V.J. Arán, *Chem. Med. Chem.* 2018, 13, 1246-1259.
- 11 C. Marín, I. Ramírez-Macías, M.J. Rosales, B. Muro, F. Reviriego, P. Navarro, V.J. Arán and M. Sánchez-Moreno, Acta Trop., 2015, **148**, 170-178.
- 12 L. Boiani, A. Gerpe, V.J. Arán, S. Torres de Ortiz, E. Serna, N. Vera de Bilbao, L. Sanabria, G. Yaluff, H. Nakayama, A. Rojas de Arias, J.D. Maya, J.A. Morello, H. Cerecetto and M. González, *Eur. J. Med. Chem.* 2009, **44**, 1034-1040.
- 13 J. M. Dickinson, Natural Product Reports 1993, 10, 71-98.
- 14 G.P. McGlacken and I.J.S. Fairlamb, Natural Product Reports 2005, 22, 369-385.
- 15 I.J.S. Fairlamb, L.R. Marrison, J.M. Dickinson, F.-J. Lu, J.P. Schmidt, Bioorg. Med. Chem. 2004, 12, 4285-4299.
- 16 A. Goel and V. J. Ram, Tetrahedron 2009, 65, 7865-7913.
- 17 A.G. Tempone, D.D. Ferreira, M.L. Lima, T.A. Costa Silva, S.E.T. Borborema, J.Q. Reimão, M.K. Galuppo, J.M. Guerra, A.J. Russell, G.M. Wynne, R.Y.L. Lai, M.M. Cadelis and B.R. Copp, *Eur. J. Med. Chem.* 2017, **139**, 947-960.
- 18 O. Kayser, A.F. Kiderlen and S.L. Croft, Acta Trop. 2003, 86, 105-107.
- 19 M. El Ghozlani, H. Chicha, N. Abbassi, M. Chigr, L. El Ammari, M. Saadi, D. Spinelli and E.M. Rakib, *Tetrahedron Lett.*, 2016, **57**, 113-117.
- 20 M. El Ghozlani, E.M. Rakib, A. Gamouh, M. Saadi, L. El Ammari, Acta Crystallogr. Sect., 2014, E70, o1256.
- 21 K. Balaraman, N.C. Vieira, F. Moussa, J. Vacus, S. Cojean, S. Pomel, C. Bories, B. Figadère, V. Kesavan, P.M. Loiseau, Biomed Pharmacother. 2015, 76, 127-133.